Volume 19, Issue 10 p. 1175-1182

Brief Report

Impact of dopamine transporter SPECT using ¹²³I-Ioflupane on diagnosis and management of patients with clinically uncertain parkinsonian syndromes^†

Ana M. Catafau MD,

Ana M. Catafau MD

Institut de Recerca, Hospital de Sant Pau, Barcelona, Spain

Search for more papers by this author

Eduardo Tolosa MD,

Corresponding Author

Eduardo Tolosa MD

[email protected]

Parkinson's Disease and Movement Disorders Unit, Neurology Service, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Hospital Clínic, Barcelona, Spain

Parkinson's Disease and Movement Disorders Unit, Neurology Service, Hospital Clínic, c/ Villarroel, 170, 08036, Barcelona, SpainSearch for more papers by this author

Ana M. Catafau MD,

Ana M. Catafau MD

Institut de Recerca, Hospital de Sant Pau, Barcelona, Spain

Search for more papers by this author

Eduardo Tolosa MD,

Corresponding Author

Eduardo Tolosa MD

[email protected]

Parkinson's Disease and Movement Disorders Unit, Neurology Service, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Hospital Clínic, Barcelona, Spain

Parkinson's Disease and Movement Disorders Unit, Neurology Service, Hospital Clínic, c/ Villarroel, 170, 08036, Barcelona, SpainSearch for more papers by this author

First published: 22 April 2004

https://doi.org/10.1002/mds.20112

Citations: 219

^†

Members of The DaTSCAN CUPS Study Group are listed in Appendix.

Share a link

Email
Facebook
Twitter
LinkedIn
Reddit
Wechat

Abstract

Imaging with ¹²³I-Ioflupane single-photon emission computed tomography (SPECT) is a marker of nigrostriatal neuronal integrity, allowing differentiation of parkinsonism with loss of dopaminergic terminals (presynaptic Parkinson syndrome [PS]) from parkinsonism without nigrostriatal degeneration. This study assessed SPECT imaging in 118 patients with clinically uncertain parkinsonian syndromes (CUPS). In 36% of patients with presynaptic PS and 54% with nonpresynaptic PS, imaging results were not consistent with the initial diagnosis. After imaging, diagnosis was changed in 52% of patients. All patients with a final diagnosis of presynaptic PS had an abnormal image, whereas 94% of patients with nonpresynaptic PS had a normal scan. Imaging increased confidence in diagnosis, leading to changes in clinical management in 72% of patients. Consequently, visual assessment of ¹²³I-Ioflupane SPECT may have a significant impact on the clinical management of CUPS patients. © 2004 Movement Disorder Society

REFERENCES

1 Brooks DJ, Playford ED, Ibanez V, et al. Isolated tremor and disruption of the nigrostriatal dopaminergic system: an ¹⁸F-dopa PET study. Neurology 1992; 42: 1554–1560.
10.1212/WNL.42.8.1554
CASPubMedWeb of Science®Google Scholar
2 Cohen O, Pullman S, Jurewicz E, Watner D, Louis ED. Rest tremor in patients with Essential Tremor, prevalence, clinical correlates and electrophysiology characteristics. Arch Neurol 2003; 60: 405–410.
10.1001/archneur.60.3.405
PubMedWeb of Science®Google Scholar
3 Hughes AJ, Daniel SE, Lees AJ. Improved accuracy of clinical diagnosis of Lewy body Parkinson's disease. Neurology 2001; 57: 1497–1499.
10.1212/WNL.57.8.1497
CASPubMedWeb of Science®Google Scholar
4 Rajput AH, Rozdilsky B, Rajput A. Accuracy of clinical diagnosis in parkinsonism: a prospective study. Can J Neurol Sci 1991; 18: 275–278.
10.1017/S0317167100031814
CASPubMedWeb of Science®Google Scholar
5 Hughes AJ, Daniel SE, Kilford L, Lees AJ. Accuracy of clinical diagnosis of idiopathic Parkinson's disease: a clinico-pathological study of 100 cases. J Neurol Neurosurg Psychiatry 1992; 55: 181–184.
10.1136/jnnp.55.3.181
CASPubMedWeb of Science®Google Scholar
6 Quinn N. Parkinsonism: recognition and differential diagnosis. BMJ 1995; 310: 447–452.
10.1136/bmj.310.6977.447
CASPubMedWeb of Science®Google Scholar
7 Meara J, Bhowmick BK, Hobson P. Accuracy of diagnosis in patients with presumed Parkinson's disease. Age Ageing 1999; 28: 99–102.
10.1093/ageing/28.2.99
CASPubMedWeb of Science®Google Scholar
8 Kaufman MJ, Madras BK. Severe depletion of cocaine recognition sites associated with the dopamine transporter in Parkinson's-diseased striatum. Synapse 1991; 9: 43–49.
10.1002/syn.890090107
CASPubMedWeb of Science®Google Scholar
9 Niznik HB, Fogel EF, Fassos FF, Seeman P. The dopamine transporter is absent in parkinsonian putamen and reduced in caudate nucleus. J Neurochem 1991; 56: 192–198.
10.1111/j.1471-4159.1991.tb02580.x
CASPubMedWeb of Science®Google Scholar
10 Neumeyer JL, Wang S, Gao Y, et al. N-omega-fluoroalkyl analogues of (1R)-2 beta-carbomethoxy-3 beta-(4-iodophenyl)-tropane (beta-CIT): radiotracers for positron emission tomography and single photon emission computed tomography imaging of dopamine transporters. J Med Chem 1994; 37: 558–561.
10.1021/jm00037a004
CASWeb of Science®Google Scholar
11 Booij J, Andringa G, Rijks LJ, et al. 123I-FP-CIT binds to the dopamine transporter as assessed by biodistribution studies in rats and SPECT studies in MPTP-lesioned monkeys. Synapse 1997; 27: 183–190.
10.1002/(SICI)1098-2396(199711)27:3<183::AID-SYN4>3.0.CO;2-9
CASPubMedWeb of Science®Google Scholar
12 Booij J, Hemelaar TG, Speelman JD, de Bruin K, Janssen AG and van Royen EA. One-day protocol for imaging of the nigrostriatal dopaminergic pathway in Parkinson's disease by [¹²³I]FPCIT SPECT. J Nucl Med 1999; 40: 753–761.
CASPubMedWeb of Science®Google Scholar
13 Benamer TS, Patterson J, Grosset DG, Booij J, et al. Accurate differentiation of parkinsonism and essential tremor using visual assessment of [¹²³I]-FP-CIT SPECT imaging: the ¹²³I-FP-CIT study group. Mov Disord 2000; 15: 503–510.
10.1002/1531-8257(200005)15:3<503::AID-MDS1013>3.0.CO;2-V
CASPubMedWeb of Science®Google Scholar
14 Booij J, Speelman JD, Horstink M, Wolters EC. The clinical benefit of imaging striatal dopamine transporters with ¹²³I-FP-CIT SPECT in differentiating patients with presynaptic parkinsonism from those with other forms of parkinsonism. Eur J Nucl Med 2001; 28: 266–272.
10.1007/s002590000460
CASPubMedWeb of Science®Google Scholar
15 Radiology Support Devices Inc. Striatal phantom for SPECT, PET and MRI. 1904 E. Dominguez St., Long Beach, CA 90810, USA.
Google Scholar
16 Lokkegaard A, Werdelin LM, Friberg L. Clinical impact of diagnostic SPET investigations with a dopamine re-uptake ligand. Eur J Nucl Med 2002; 29: 1623–1629.
10.1007/s00259-002-0938-7
CASPubMedWeb of Science®Google Scholar
17 Jankovic J, Rajput AH, McDermott MP, Perl DP, for the Parkinson Study Group. The evolution of diagnosis in early Parkinson Disease. Arch Neurol 2000; 57: 369–372.
10.1001/archneur.57.3.369
CASPubMedWeb of Science®Google Scholar
18 Larsen JP, Dupont E, Tandberg E. Clinical diagnosis of Parkinson's disease. Proposal of diagnostic subgroups classified at different levels of confidence. Acta Neurol Scand 1994; 89: 242–251.
10.1111/j.1600-0404.1994.tb01674.x
CASPubMedWeb of Science®Google Scholar

Citing Literature

Volume19, Issue10

October 2004

Pages 1175-1182

Impact of dopamine transporter SPECT using ¹²³I-Ioflupane on diagnosis and management of patients with clinically uncertain parkinsonian syndromes^†

Abstract

REFERENCES

Citing Literature

References

Information

RESOURCES

About Wiley Online Library

Help & Support

Opportunities

Connect with Wiley

Impact of dopamine transporter SPECT using 123I-Ioflupane on diagnosis and management of patients with clinically uncertain parkinsonian syndromes†

Abstract

REFERENCES

Citing Literature

References

Related

Information

RESOURCES

Impact of dopamine transporter SPECT using ¹²³I-Ioflupane on diagnosis and management of patients with clinically uncertain parkinsonian syndromes^†